Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
21-40 of 1,782 trials

Febrile Neutropenia: SAFE Study on Short Antibiotic Treatment

We are studying whether stopping antibiotics after 3 days is as safe as continuing them longer for patients with febrile neutropenia. This research aims to find a potentially safer treatment approach for hematology patients.

Febrile Neutropenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Anemia in Low-Risk Myelodysplastic Syndrome: Luspatercept vs Epoetin Alfa

We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.

Myelodysplastic Syndrome (MDS)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Preventing Dementia: Metformin and Lifestyle Changes

We are studying whether a combination of metformin and a structured lifestyle program can help older adults at risk for dementia improve their cognitive abilities and overall health compared to a self-guided approach.

Cognitive Impairment Prevention>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyNeurology

HER2 Status in Solid Tumors: [68Ga]Ga-ABY-025 PET Study

We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.

Breast CancerGastro-esophageal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Glioblastoma: Early Intensified Treatment with Temozolomide

We are studying whether starting chemotherapy earlier with temozolomide helps adults with glioblastoma live longer compared to standard treatment. The trial also examines safety and treatment effectiveness.

Glioblastoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Multiple Myeloma: Isatuximab and Lenalidomide Study

We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Marstacimab for Severe Hemophilia A and B

We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.

Haemophilia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Myelodysplastic Syndrome: Oral Azacitidine Study

We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes (MDS)>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesHematology

Fabry Disease: Migalastat for Kidney Impairment

We are studying the safety and how the body processes migalastat in people with Fabry disease and severe kidney impairment on dialysis. This research aims to ensure the right dosing for these patients.

Fabry Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal MedicineNephrology

Marstacimab for Pediatric Hemophilia

We are studying a new treatment for children with severe hemophilia A or B to see if it is safer and more effective than standard care. This trial includes participants with or without inhibitors.

Haemophilia1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

BOTOX for Masseter Muscle Prominence

We are studying whether BOTOX injections can help reduce the prominence of the masseter muscle in adults. This trial compares BOTOX to a placebo to evaluate its effectiveness and safety.

Masseter Muscle Prominence1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementDermatology

Prostate Cancer: Lutetium-177 vs. Standard Treatments

We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.

Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Individualized Immunotherapy for Early-Stage Hodgkin Lymphoma

We are testing a new personalized treatment using tislelizumab for adults with early-stage unfavorable classical Hodgkin lymphoma. The goal is to see if this approach improves treatment outcomes and is safe for patients.

Early-Stage Unfavorable Classical Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Waldenström’s Macroglobulinemia: Venetoclax with Rituximab

We are studying whether the combination of Venetoclax and Rituximab is more effective than standard treatments for patients with Waldenström’s Macroglobulinemia. This research aims to find better options for managing this condition.

Waldenström's Macroglobulinemia1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Wet Cough in Children: The AMIC Study

We are investigating whether antibiotics can help children with chronic wet cough and how different treatment durations affect their recovery. The study also looks at the role of gut and airway bacteria in their health.

Chronic Wet Cough in Young Children6-12 monthsMonitoring phase (IV)Standard MedicinesInfectious DiseasesPulmonology

Tranexamic Acid for Spontaneous Brain Bleeding

We are studying whether tranexamic acid can help reduce early deaths in patients with spontaneous intracerebral hemorrhage. Additionally, we will look at its effects on recovery six months later.

Stroke3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurology

Xenon Treatment for Brain Injury After Aneurysmal Subarachnoid Hemorrhage

We are investigating whether xenon gas can help protect the brain and improve recovery in patients who have experienced a specific type of brain bleed. This study will also look at the safety and effects of xenon on neurological outcomes.

Aneurysmal Subarachnoid Hemorrhage6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Prostate Medication and Gut Health Study

We are investigating how prostate treatments affect gut bacteria and how these bacteria may influence treatment responses in men with BPH and prostate cancer.

Prostate CancerBenign Prostate Hyperplasia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineUrology

Immunotherapy for Early dMMR Rectal Cancer

We are studying the effects of nivolumab and ipilimumab in patients with stage 1-3 dMMR rectal cancer. The goal is to see how effective and tolerable this treatment is.

Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology